Indolent Lymphoma - Pipeline Review, H1 2016

  • ID: 3641069
  • Report
  • 218 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche Ltd.
  • Incyte Corporation
  • MORE
Indolent Lymphoma - Pipeline Review, H1 2016

Summary

‘Indolent Lymphoma - Pipeline Review, H1 2016’, provides an overview of the Indolent Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Indolent Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Indolent Lymphoma and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Indolent Lymphoma
- The report reviews pipeline therapeutics for Indolent Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Indolent Lymphoma therapeutics and enlists all their major and minor projects
- The report assesses Indolent Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Indolent Lymphoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Indolent Lymphoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Indolent Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche Ltd.
  • Incyte Corporation
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Indolent Lymphoma Overview

Therapeutics Development

Pipeline Products for Indolent Lymphoma - Overview

Indolent Lymphoma - Therapeutics under Development by Companies

Indolent Lymphoma - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Indolent Lymphoma - Products under Development by Companies

Indolent Lymphoma - Companies Involved in Therapeutics Development

AbbVie Inc.

Affimed Therapeutics AG

Altor BioScience Corporation

Astellas Pharma Inc.

AstraZeneca Plc

Bayer AG

Biothera, Inc.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celgene Corporation

F. Hoffmann-La Roche Ltd.

Gilead Sciences, Inc.

Incyte Corporation

Infinity Pharmaceuticals, Inc.

Juno Therapeutics Inc.

Kite Pharma, Inc.

MedImmune, LLC

Merck & Co., Inc.

Merck KGaA

Millennium Pharmaceuticals, Inc.

MorphoSys AG

Trillium Therapeutics Inc.

Indolent Lymphoma - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

acalisib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AFM-11 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ALT-803 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AZD-6738 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

bendamustine hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BI-836826 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BMS-986016 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BTH-1677 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CC-122 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

copanlisib hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

DI-B4 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

duvelisib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

entospletinib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ibrutinib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

idelalisib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

INCB-40093 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

INCB-50465 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

inebilizumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

inebilizumab + MEDI-0680 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

inebilizumab + rituximab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

itacitinib adipate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

JCAR-014 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

JCAR-015 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

KTEC-19 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

lenalidomide - Drug Profile

Product Description

Mechanism of Action

R&D Progress

MOR-208 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

obinutuzumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TAK-659 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TTI-621 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

venetoclax - Drug Profile

Product Description

Mechanism of Action

R&D Progress

vorinostat - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Indolent Lymphoma - Recent Pipeline Updates

Indolent Lymphoma - Dormant Projects

Indolent Lymphoma - Discontinued Products

Indolent Lymphoma - Product Development Milestones

Featured News & Press Releases

Nov 30, 2015: New Data from Bayer’s Portfolio in Oncology to be Presented at ASH 2015

Dec 01, 2014: Bayer To Present Phase II Clinical Trials Data On Copanlisib At ASH 56th Annual Meeting

Apr 07, 2014: Research Expands Understanding of Biomarker for Biothera Cancer Immunotherapy Imprime PGG

Jan 22, 2014: New drug shows promise in treating indolent non-Hodgkin lymphomas

Dec 10, 2013: Studies Evaluating REVLIMID (Lenalidomide) in Lymphoma Presented at ASH

Dec 08, 2013: Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent Non-Hodgkin’s Lymphoma

Feb 20, 2013: Phase 3 data published in The Lancet show bendamustine plus rituximab doubles progression-free survival in patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma compared with CHOP-R

Dec 10, 2012: Infinity Pharma Reports IPI-145 Phase I Data Showing Clinical Activity In B-Cell And T-Cell Malignancies At ASH Annual Meeting

Dec 03, 2012: Record number of bendamustine abstracts accepted for presentation at the Annual Meeting of the American Society of Hematology (ASH)

Dec 07, 2010: Celgene Presents Clinical Data From Two Phase II Studies Evaluating REVLIMID Plus Rituximab In Indolent Non-Hodgkin’s Lymphomas At ASH

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Indolent Lymphoma, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Indolent Lymphoma - Pipeline by AbbVie Inc., H1 2016

Indolent Lymphoma - Pipeline by Affimed Therapeutics AG, H1 2016

Indolent Lymphoma - Pipeline by Altor BioScience Corporation, H1 2016

Indolent Lymphoma - Pipeline by Astellas Pharma Inc., H1 2016

Indolent Lymphoma - Pipeline by AstraZeneca Plc, H1 2016

Indolent Lymphoma - Pipeline by Bayer AG, H1 2016

Indolent Lymphoma - Pipeline by Biothera, Inc., H1 2016

Indolent Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2016

Indolent Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2016

Indolent Lymphoma - Pipeline by Celgene Corporation, H1 2016

Indolent Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016

Indolent Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2016

Indolent Lymphoma - Pipeline by Incyte Corporation, H1 2016

Indolent Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2016

Indolent Lymphoma - Pipeline by Juno Therapeutics Inc., H1 2016

Indolent Lymphoma - Pipeline by Kite Pharma, Inc., H1 2016

Indolent Lymphoma - Pipeline by MedImmune, LLC, H1 2016

Indolent Lymphoma - Pipeline by Merck & Co., Inc., H1 2016

Indolent Lymphoma - Pipeline by Merck KGaA, H1 2016

Indolent Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016

Indolent Lymphoma - Pipeline by MorphoSys AG, H1 2016

Indolent Lymphoma - Pipeline by Trillium Therapeutics Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Indolent Lymphoma Therapeutics - Recent Pipeline Updates, H1 2016

Indolent Lymphoma - Dormant Projects, H1 2016

Indolent Lymphoma - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Indolent Lymphoma, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
AbbVie Inc.
Affimed Therapeutics AG
Altor BioScience Corporation
Astellas Pharma Inc.
AstraZeneca Plc
Bayer AG
Biothera, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corporation
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
Incyte Corporation
Infinity Pharmaceuticals, Inc.
Juno Therapeutics Inc.
Kite Pharma, Inc.
MedImmune, LLC
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
MorphoSys AG
Trillium Therapeutics Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll